Delivery Order SPE2DR25D1021-SPE2DR26FNS7M
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $82,519.49 to AmerisourceBergen Drug Corp on January 15, 2026, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 16, 2026. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $45,798 delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets (30-count units) on January 23, 2026, with an ultimate completion date of January 26, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company, Cencora, Inc.'s larger...
- The Defense Logistics Agency awarded a delivery order valued at $26,892.34 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $6,762.36 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on January 13, 2026, with an ultimate completion date of January 14, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single task order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $54.3K delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania and an ultimate completion date of January 7, 2026. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.9M vehicle valued...
- The Defense Logistics Agency awarded a delivery order valued at $11,382.77 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on January 22, 2026, with a completion date of January 23, 2026. The award is non-set-aside and structured as a firm fixed-price delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with its parent company Cencora, Inc. (doing business as AmerisourceBergen) providing...
- The Defense Logistics Agency awarded a $21,471.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 20, 2026, for the supply of RINVOQ ER 30 mg tablets (30-count units), with a completion date of January 21, 2026. This non-set-aside delivery order will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $6,558.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 8, 2025, with completion targeted for December 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a $19,675.26 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of RINVOQ ER 15mg tablets (30-count bottles). This is a firm fixed-price, non-set-aside contract with a completion date of January 14, 2026, and performance location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D1021Indefinite Delivery Contract
- SPE2DR25D1021-SPE2DR26FNS7MDelivery Order
The Defense Logistics Agency awarded a $35.9K firm fixed-price delivery order to AmerisourceBergen Drug Corp on February 2, 2026, for the supply of RINVOQ ER 30 mg tablets in quantities of 30-unit packages. This delivery order represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99M through December 2026, which serves as the primary vehicle for pharmaceutical and medical supply distribution to military healthcare systems worldwide. The contract is not set-aside and was competitively awarded. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of February 3, 2026. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., operates as a major pharmaceutical distributor serving federal government agencies, particularly the Department of Defense and veterans' healthcare systems. The company's extensive contract portfolio demonstrates consistent capability to supply brand-name and generic medications across multiple therapeutic domains. RINVOQ (upadacitinib) is a JAK inhibitor indicated for inflammatory conditions, and this delivery order reflects the contractor's role in providing specialized pharmaceutical products to support military medical treatment facilities and defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.9k | 2/1/26 |